Open Access

Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review)

  • Authors:
    • Eugenio Cavalli
    • Alessia Bramanti
    • Rosella Ciurleo
    • Andrey I. Tchorbanov
    • Antonio Giordano
    • Paolo Fagone
    • Cristina Belizna
    • Placido Bramanti
    • Yehuda Shoenfeld
    • Ferdinando Nicoletti
  • View Affiliations

  • Published online on: June 25, 2020     https://doi.org/10.3892/ijmm.2020.4659
  • Pages: 903-912
  • Copyright: © Cavalli et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a novel β coronavirus that is the etiological agent of the pandemic coronavirus disease 2019 (COVID‑19) that at the time of writing (June 16, 2020) has infected almost 6 million people with some 450,000 deaths. These numbers are still rising daily. Most (some 80%) cases of COVID‑19 infection are asymptomatic, a substantial number of cases (15%) require hospitalization and an additional fraction of patients (5%) need recovery in intensive care units. Mortality for COVID‑19 infection appears to occur globally between 0.1 and 0.5% of infected patients although the frequency of lethality is significantly augmented in the elderly and in patients with other comorbidities. The development of acute respiratory distress syndrome and episodes of thromboembolism that may lead to disseminated intravascular coagulation (DIC) represent the primary causes of lethality during COVID‑19 infection. Increasing evidence suggests that thrombotic diathesis is due to multiple derangements of the coagulation system including marked elevation of D‑dimer that correlate negatively with survival. We propose here that the thromboembolic events and eventually the development of DIC provoked by SARS‑CoV‑2 infection may represent a secondary anti‑phospholipid antibody syndrome (APS). We will apply both Baconian inductivism and Cartesian deductivism to prove that secondary APS is likely responsible for coagulopathy during the course of COVID‑19 infection. Diagnostic and therapeutic implications of this are also discussed.

Related Articles

Journal Cover

September-2020
Volume 46 Issue 3

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cavalli E, Bramanti A, Ciurleo R, Tchorbanov AI, Giordano A, Fagone P, Belizna C, Bramanti P, Shoenfeld Y, Nicoletti F, Nicoletti F, et al: Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review). Int J Mol Med 46: 903-912, 2020
APA
Cavalli, E., Bramanti, A., Ciurleo, R., Tchorbanov, A.I., Giordano, A., Fagone, P. ... Nicoletti, F. (2020). Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review). International Journal of Molecular Medicine, 46, 903-912. https://doi.org/10.3892/ijmm.2020.4659
MLA
Cavalli, E., Bramanti, A., Ciurleo, R., Tchorbanov, A. I., Giordano, A., Fagone, P., Belizna, C., Bramanti, P., Shoenfeld, Y., Nicoletti, F."Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review)". International Journal of Molecular Medicine 46.3 (2020): 903-912.
Chicago
Cavalli, E., Bramanti, A., Ciurleo, R., Tchorbanov, A. I., Giordano, A., Fagone, P., Belizna, C., Bramanti, P., Shoenfeld, Y., Nicoletti, F."Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review)". International Journal of Molecular Medicine 46, no. 3 (2020): 903-912. https://doi.org/10.3892/ijmm.2020.4659